A61P 21 - Drugs for disorders of the muscular or neuromuscular system

Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
11/2007
11/15/2007	US20070265188 LDL Receptor-Related Proteins 1 and 2 and Treatment of Bone or Cartilage Conditions
11/15/2007	US20070264345 liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, 26.7-40.0%, propylene-glycol, 13.3-20.0%, isopropyl myristate, 5.0-35.0%, ethanol, 0.01-10.0%, benzyl alcohol, 0.5-1.5%, a hyaluronic acid salt or complex 0.01-2.00%, and purified water, 12.5-26.5%; healing cosmetics
11/15/2007	US20070264245 Compositions and minimally invasive methods for treating incomplete tissue repair
11/15/2007	US20070264232 Cell populations which co-express CD49c and CD90
11/15/2007	US20070264230 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
11/15/2007	US20070264229 Peptides for Treatment of Autoimmune Disease
11/15/2007	CA2650718A1 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
11/14/2007	EP1853538A2 Modulator
11/14/2007	EP1853293A1 Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
11/14/2007	EP1853280A2 Compositions and methods for treating and preventing cardiomyopathy and heart disease
11/14/2007	EP1853262A1 Pharmaceutical composition comprising amorphous rosiglitazone
11/14/2007	EP1469835B1 Stable salts of o-acetylsalicylic acid containing basic amino acids ii
11/14/2007	EP1427722B1 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression
11/14/2007	EP1423012B1 Medical use of stem cells expressing vegfr-1
11/14/2007	EP1373503B1 Neurotrophic factors
11/14/2007	EP1368048B1 Pharmaceutical composition made of cannabis extracts
11/14/2007	EP1286691B1 Methods for treatment of diseases associated with acute inflammation under non-ischemic conditions
11/14/2007	EP1114156B1 Mammalian transforming growth factor beta - 9 (ztgfss9)
11/14/2007	CN101072815A Polymeric polphenol extracted for fermented tea, therapeutic agent for mitochondrial disease, preventive/therapeutic agent for diabetes mellitus, and food or beverage
11/14/2007	CN101072509A Treatment and prevention of inflammatory disorders
11/14/2007	CN101069675A A method of alleviating signs and symptons of spasticity
11/14/2007	CN100348605C Colchicoside analogues
11/13/2007	US7294720 N3-(hydroxy- or alkoxyphenyl) amidrazone, e.g., N3-[3-Methoxyphenyl]-p-tert-butyl-benzamidrazone, are intermediates for preparing phenyl-1,2,4-triazoles, e.g., 1-{3-[4-(tert-Butyl)phenyl]-(1,2,4-triazol-4-yl)}-3-methoxybenzene
11/08/2007	WO2007125246A1 Use of a tricyclic compound for preparing a medicine for treating skeletal muscle degeneration
11/08/2007	WO2007125245A1 Use of a compound inducing an increase of free serotonin rate in the body, for preparing a medicine for treating skeletal muscle degeneration
11/08/2007	US20070259912 Polymorphic forms of a GABAA agonist
11/08/2007	US20070259891 Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors
11/08/2007	US20070259887 Inhibitors of polyq-aggregation
11/08/2007	US20070259882 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
11/08/2007	US20070259837 Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy
11/08/2007	US20070259816 Expression vector comprising nucleotide sequences coding homeobox gene for use in identifying modulators for treatment and prevention of nervous system and seizure disorders
11/08/2007	US20070259401 Single-chain polypeptide fusion comprising functional binding, translocation and clostridial neurotoxin heavy chain domain for use as therapeutic agents and/or transporter molecules
11/08/2007	US20070258992 Clostridial peptide for preventing or reducing immunoresistance to botulinum toxin therapy in humans and/or other mammals
11/08/2007	US20070258974 Diagnostics and Therapeutics for Diseases Associated with Puromycin Sensitive Aminopeptidase Npepps (Npepps)
11/07/2007	EP1852505A1 Mutations in ion channels
11/07/2007	EP1852503A1 Il-13 production inhibitor
11/07/2007	EP1144671B1 Enriched central nervous system cell populations
11/07/2007	CN101068539A Supplemental dietary composition for enhancing muscle performance and/or recovery from fatigue
11/07/2007	CN101066997A Human antibodies that bind human IL-12 and methods for producing
11/07/2007	CN101066319A Chinese medicine composition for treating flaccidity syndrome
11/07/2007	CN100346823C Enamel matrix protein compositions for modulating immune response
11/07/2007	CN100346792C Benzothiazole derivatives as adenosine receptor ligands
11/07/2007	CN100346779C Liquid pharmaceutical composition
11/06/2007	US7291633 nicotinic alpha 7 receptor and 5-HT3 or 5-HT6 receptor; control of cholinergic and dopaminergic neurotransmission; disorders of the central nervous system and serotonergic hyperactivity; psychiatric and neurodegenerativce disorders; antiemetics during chemotherapy
11/06/2007	US7291630 Azaindoles as inhibitors of c-Jun N-terminal kinases
11/06/2007	US7291624 Enzyme inhibitors as drugs for cardiovascular disorders, aids, alzheimers disease or urogenital disorders
11/06/2007	US7291595 Administering to the patient about 15 to about 360 mg of alpha-1-antitrypsin per kg patient body mass, and repeating the administration at least once with a periodicity of between 3 and 31 days
11/06/2007	US7291451 Modulation of pericyte proliferation
11/06/2007	US7291330 MD-1 inhibitors as immune suppressants
11/01/2007	WO2007122976A1 Therapeutic agent or development inhibitor of polyglutamine disease
11/01/2007	WO2007122721A1 Fiber and fiber products for relieving symptoms of fibromuscular pain
11/01/2007	WO2007072503A3 Combinations for managing inflammation and associated disorders
11/01/2007	WO2006083183A9 Use of myostatin (gdf-8) antagonists for treatment of sarcopenia (age-related muscle-wasting)
11/01/2007	US20070254963 Ozonidzed Pharmaceutical Composition and Method
11/01/2007	US20070254875 Androgen Receptor Modulator Compounds and Methods
11/01/2007	US20070254028 Granules Comprising a Nsaid and a Sugar Alcohol Made by Melt Extrusion
11/01/2007	CA2649820A1 Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof
10/2007
10/31/2007	EP1849801A1 Tyrosine-based motif and clostridial neurotoxins
10/31/2007	EP1849462A2 A method of alleviating signs and symptons of Spasticity
10/31/2007	EP1513821B1 Protein kinase inhibitors
10/31/2007	EP1289993B1 Caspase inhibitors and uses thereof
10/31/2007	EP1177312B1 Human gil-19/ae289 proteins and polynucleotides encoding same
10/31/2007	EP0910564B1 D-amino acid derived inhibitors of cysteine and serine proteases
10/31/2007	DE60126947T2 Behandlung der glykogenspeicherkrankheit typ ii Treatment of glycogen storage disease type ii
10/31/2007	CN101062037A Thioxanthine derivatives, process for their preparation (variants), their use and composition containing them
10/31/2007	CN101062009A Therapeutikum mit einem botulinum-neurotoxin
10/31/2007	CN100345840C Stable hydrate of a muscarinic receptor antagonist
10/31/2007	CN100345834C 异羟肟酸衍生物 Hydroxamic acid derivatives
10/31/2007	CN100345829C Pyrimidyl sulphone amide derivatives as chemokine receptor modulators
10/30/2007	US7288568 Alzheimer's disease; Parkinson's disease; inflammatory bowel disease; antiarthritic agents
10/30/2007	US7288564 Analgesics, antiinflammatory agents, autoimmune diseases, bone disorders, central nervous system disorders
10/30/2007	US7288390 Anti-dual integrin antibodies, compositions, methods and uses
10/30/2007	CA2186760C Use of biopolymers for the muscle treatment
10/26/2007	CA2586392A1 A method for alleviating signs and symptoms of spasticity
10/25/2007	WO2007119833A1 Nitrogen-containing heterocyclic compound
10/25/2007	US20070249725 Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain
10/25/2007	US20070249617 3-(6-p-Tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane; treatment of psychotic disorders such as schizophrenia, mania, depression and anxiety; neurodegenerataive disorders such as senile dementia, Alzhelmer's disease and other intellectual impairment disorders
10/25/2007	US20070248674 Hydrogel Interferon Formulations
10/25/2007	US20070248590 Modulators of CDC2-like kinases (CLKS) and methods of use thereof
10/25/2007	CA2648748A1 Nitrogen-containing heterocyclic compound
10/24/2007	EP1847550A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
10/24/2007	CN101060794A The use of anti-oxidant compounds for muscle recovery
10/24/2007	CN101057970A Therapeutic vaccine for Myostatin specific antibody and its preparation method
10/24/2007	CN100344648C Cyclosporine analogue mixtures and their use as immunomodulating agents
10/24/2007	CN100344316C Chinese medicine for treating myasthenia gravis
10/23/2007	US7285560 E.g., N-[(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]oxadizol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide; used for treating rheumatoid arthritis, osteoarthritis, asthma, cardiac infarction, Alzheimer's diseases, cancer diseases or atherosclerosis
10/23/2007	US7285525 Suppression of immune response via inhibition of cathepsin S
10/18/2007	WO2007117022A1 Chewing composition comprising coenzyme q10
10/18/2007	WO2007116962A1 Muscle regeneration promoter
10/18/2007	WO2007115776A1 USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY
10/18/2007	WO2007062000A3 Fibroblast growth factor-5 and uses thereof
10/18/2007	US20070244139 Indole Derivatives or Benzimidazole Derivatives for Modulating IkB Kinase
10/18/2007	US20070243609 Cell populations which co-express CD49c and CD90
10/18/2007	US20070243185 Suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin; containing polypeptide with an aggregation inhibitor selected from the group consisting of L-arginine and L-cysteine.
10/18/2007	CA2648644A1 Muscle regeneration promoter
10/17/2007	EP1845081A1 Amide compound
10/17/2007	EP1843791A1 Treatment of degenerative diseases with the x-linked inhibitor of apoptosis
10/17/2007	EP1843661A2 Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids
10/17/2007	EP1474395B1 Nicotinamide derivates useful as p38 inhibitors
10/17/2007	EP1173432B1 Piperidine-indole compounds having 5-ht6 affinity

1 ... 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 ... 233